Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Recombinant Influenza and COVID-19 Combination Vaccine
NCT06695130Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine, recombinant hemagglutinin and recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) and influenza (7 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 minutes, Number of participants with solicited injection site reactions at 7 days and 12 more. Started Nov 2024; status: completed.
02
Drugs
influenza vaccine, recombinant hemagglutininrecombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06695130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695130.